Fem To Second Laser
Fem To Second Laser
Fem To Second Laser
The following articles regarding the use of the femtosecond laser were reviewed:
Heisterkamp et al1 studied 10 rabbit eyes that underwent the creation of a lamellar corneal flap
and preparation of an intrastromal refractive lenticule with the help of a femtosecond laser. The
flap was lifted, the lenticule was extracted, and the flap was repositioned (also known as
intrastromal laser keratomileusis). The corneal samples were collected up to 120 days after
treatment and processed for histopathological analysis. The surgeon was able to open the flaps
and extract the prepared lenticules in one piece. The treated corneas developed a mild wound-
healing reaction, comparable to that occurring after LASIK performed with a microkeratome. The
wound healing was restricted to the flap-stroma interface and was most pronounced at the flaps
periphery.
Ratkay-Traub et al2 used a femtosecond laser in partially sighted human eyes. They performed
femtosecond laser-assisted LASIK on 46 eyes with myopia of up to -14.00D. Sixteen patients
received intracorneal ring segments (ICRS). Five patients, each with one highly myopic eye,
underwent femtosecond laser-assisted keratomileusis. Thirteen patients, each with one myopic or
hyperopic eye, had intrastromal ablation PRK. With femtosecond laser keratomileusis, a lens-
shaped block of stroma is removed manually from beneath the flap. The investigators found no
differences between results obtained with LASIK performed with a femtosecond laser and a
standard microkeratome. Those patients who received ICRS also received femtosecond laser-
prepared channels and conventionally placed ICRS and produced the same refractive results.
With ICRS placed using the femtosecond laser, no intraoperative complications occurred, and
visual acuity improved immediately after surgery.
By generating microplasmas inside the corneal stroma with femtosecond pulses, it is possible to
achieve a cutting effect inside the tissue while leaving the anterior layers of the eye intact. The
energy threshold to generate microplasma with femtosecond pulses is some orders of magnitude
lower than it is for pico- or nanosecond pulses. Use of the lower energy results in a significant
reduction of the thermal and mechanical damage of the surrounding tissue. Investigators studied
the cutting effect on corneal tissue from freshly enucleated porcine globes with different pulse
energies of a titanium:sapphire femtosecond laser system.3 The laser-induced pressure
transients and bubble formations were analyzed using a broadband acoustic transducer and flash
photography. With femtosecond laser pulses, the extent of thermal and mechanical damage of
the adjacent tissue was 1m or less, comparable with tissue alterations after ArF excimer laser
ablation. Thus, using pulsed energies of approximately 1 to 2J and a spot diameter of 5 to
10m, one can precisely create intrastromal cuts to prepare corneal flaps and lenticules.
Nordan et al4 performed a prospective, consecutive series in which 208 eyes (122 patients)
underwent LASIK with the femtosecond laser for creation of the corneal flap. Patients were
evaluated during a 6-month follow-up period to monitor complications. Analysis was carried out
on a subset of 114 myopic patients. Four of 208 eyes (1.9%) lost suction during the procedure, a
problem that interrupted the flaps resection. However, re-applanation allowed the procedure to
be completed successfully. No postoperative complications or adverse events were reported in
these patients. In a subgroup of 96 eyes undergoing plano correction with a preoperative
spherical equivalent refraction ranging from -0.63 to -12.40D, 98% achieved a UCVA of 20/40 or
greater visual acuity, 79% achieved 20/25 or greater, and 55% achieved 20/20 or greater. None
of the patients required a retreatment. The investigators concluded that the laser flap technique
may offer both safety and performance advantages compared with current mechanical methods.
The smaller hinge angle allows further reflection of the flap, producing a larger, circular bed
surface area for centered ablation. In addition, the femtosecond laser produces more vertical side
cuts (70) compared with that of the microkeratome (typically 30). The smaller hinge and vertical
side cuts yield a 8.0-mm laser keratome flap comparable with a 9.5-mm microkeratome flap.
Durrie et al5 studied 51 consecutive patients who had bilateral wavefront-guided LASIK for
myopia with the Ladarvision System (Alcon Laboratories, Inc., Fort Worth, TX). One eye of each
patient was randomized to have a flap created with the Intralase FS laser (Intralase Corp., Irvine,
CA) and the other flap using a standard compression-head Hansatome microkeratome (Bausch &
Lomb, Rochester, NY). All other treatment parameters were the same. All eyes were treated
based upon their aberrometry measurements without the surgeons adjustments. Overall, the
results in both groups were excellent, with 88% of the Hansatome eyes and 98% of the Intralase
eyes achieving a UCVA of 20/20 or better at 3 months. The Intralase group had significantly
better mean UCVAs at all intervals from 1 day to 3 months postoperatively. The mean
spheroequivalent at 3 months was more myopic with the Hansatome (-0.34D 0.28) than with the
Intralase group (0.19 0.24D) (P<.01). The mean residual astigmatism at 3 months was also
significantly higher in the Hansatome group than in the Intralase group (0.32 0.25D and
0.17 0.20D, respectively) (P<.01). Aberrometry showed significantly higher astigmatism and
trefoil in the Hansatome group. The recovery of corneal sensation and epithelial integrity was
similar between the groups. The statistically better UCVA and manifest refractive outcomes after
LASIK with the Intralase FS laser may be the result of differences in postoperative astigmatism
and trefoil. Although nomogram adjustments may have improved the spheroequivalent results in
both groups, the observed increase in astigmatism and trefoil in the Hansatome group would
likely not be improved using such nomogram adjustments.
A retrospective study done by Kezirian et al6 compared LASIK outcomes with the Intralase FS
laser to those with the Carriazo-Barraquer microkeratome (Moria, Antony, France) and the
Hansatome microkeratome. All three groups were matched for enrollment criteria and were
operated on under similar conditions by the same surgeon. The investigators studied 106 eyes in
the Intralase group, 126 eyes in the Carriazo-Barraquer group, and 143 eyes in the Hansatome
group. One day postoperatively, the UCVA results in the three groups were similar. At 3 months,
the UCVA and BSCVA results were not significantly different. A manifest spheroequivalent of
0.50D was achieved in 91% of eyes in the Intralase group, 73% of eyes in the Carriazo-
Barraquer group, and 74% of eyes in the Hansatome group (P<.01). Intralase flaps were
significantly thinner (P<.01) and varied less in thickness (P<.01) than flaps created with the other
devices. The mean flap thickness was 114m 14 with the Intralase programmed for a 130-m
depth, 153 26m with the Carriazo-Barraquer using a 130-m plate, and 156 29m with the
Hansatome using a 180-m plate. Loose epithelium was encountered in 9.6% of eyes in the
Carriazo-Barraquer group and 7.7% of eyes in the Hansatome group, but in no eyes in the
Intralase group (P=.001). Surgically induced astigmatism in sphere corrections was significantly
less with the Intralase than with the other devices (P<.01). The investigators concluded that the
Intralase produced more predictable flap thickness, better astigmatic neutrality, and less epithelial
injury than mechanical microkeratomes.
Tran et al7 performed a randomized prospective study of nine patients (18 eyes) treated with a
two-step LASIK procedure: lamellar keratectomy with a Hansatome microkeratome or the
Intralase FS laser in the fellow eye followed by nonwavefront-guided excimer laser treatment 10
weeks later.8 The fellow eyes were matched within of 0.75D sphere and 0.50D of cylinder.
Patients were followed for 3 months after excimer laser treatment. Wavefront aberrometry and
manifest refraction were evaluated before and after flap creation. Statistically significant changes
were seen in defocus wavefront aberrations after Hansatome (P=.004) and Intralase (P=.008)
flap creation. A hyperopic shift in manifest refraction was noted in the Hansatome group after the
corneal flap was created (P=.04), while no statistically significant changes in the manifest
refraction were seen in the Intralase group. Statistically significant changes in total higher-order
aberrations (trefoil and quadrafoil) occurred following flap creation in the Hansatome group
(P=.02). No significant changes in higher-order aberrations were noted after flap creation in the
Intralase group.
Femtosecond lasers produce precise intrastromal incisions, which improves safety and reduces
the incidence of corneal trauma, partial resections, or sterilization issues.
The femtosecond laser may be a better option than the Hansatome microkeratome for treating
and preventing higher-order aberrations after LASIK.
Additional comparative studies of PRK and femtosecond laser-assisted LASIK could help
determine which treatment modality is best for wavefront-guided treatments.
The femtosecond laser has the potential to create intrastromal refractive lenticules for complete
refractive procedures, such as intrastromal laser keratomileusis.
Femtosecond laser-assisted ICRS is associated with a speedy recovery of vision and minimal
surgical trauma compared with using a blade to make a channel.
The laser also allows surgeons to control the channels width precisely, perhaps thereby
optimizing the rate and stability of visual recovery after ICRS surgery.
Reviewer
Lav Panchal, MD, states that he holds no financial interest in any product or company mentioned
herein.
Dr. Panchal may be reached at (917) 751-8651;
[email protected].
Panel Members
Y. Ralph Chu, MD, is Medical Director, Chu Vision Institute in Edina, Minnesota. He states that he
holds no financial interest in any product or company mentioned herein. Dr. Chu may be reached
at (952) 835-1235; [email protected].
Nina Goyal, MD, is a resident in ophthalmology at the Rush University Medical Center in Chicago.
She states that she holds no financial interest in any product or company mentioned herein. Dr.
Goyal may be reached at (312) 942-5315; [email protected].
Wei Jiang, MD, is a resident in ophthalmology at the Jules Stein Eye Institute in Los Angeles. She
states that she holds no financial interest in any product or company mentioned herein. Dr. Jiang
may be reached at (310) 825-5000; [email protected].
Baseer Khan, MD, is a senior resident in ophthalmology in the Department of Ophthalmology at
the University of Toronto. He states that he holds no financial interest in any product or company
mentioned herein. Dr. Khan may be reached at (415) 258-8211; [email protected].
Patty Lin, MD, MBA, is a resident in ophthalmology at the Jules Stein Eye Institute in Los
Angeles. She states that she holds no financial interest in any product or company mentioned
herein. Dr. Lin may be reached at (310) 825-5000; [email protected].
Gregory J. McCormick, MD, is a cornea and refractive fellow at the University of Rochester Eye
Institute in New York. He states that he holds no financial interest in any product or company
mentioned herein. Dr. McCormick may be reached at (585) 256-2569;
[email protected].
Jay S. Pepose, MD, PhD, is Professor of Clinical Ophthalmology & Visual Sciences, Washington
University School of Medicine, St. Louis. He states that he holds no financial interest in any
product or company mentioned herein.
Dr. Pepose may be reached at (636) 728-0111;
[email protected].
Paul Sanghera, MD, is senior resident in ophthalmology in the Department of Ophthalmology and
Vision Sciences at the University of Toronto. He states that he holds no financial interest in any
product or company mentioned herein. Dr. Sanghera may be reached at (416) 666-7115;
[email protected].
Rene Solomon, MD, is an ophthalmology fellow at Ophthalmic Consultants of Long Island in
New York. She states that she holds no financial interest in any product or company mentioned
herein. Dr. Solomon may be reached at [email protected].
Tracy Swartz, OD, MS, states that she holds no financial interest in any product or company
mentioned herein. She may be reached at (615) 321-8881;
[email protected].
Ming Wang, MD, PhD, states that he holds no financial interest in any product or company
mentioned herein. He may be reached at (615) 321-8881;
[email protected].